ANEB (Anebulo Pharmaceuticals) YoY EPS Growth: 44.44% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANEB Anebulo Pharmaceuticals Inc ANEB
35 GF Score
Price $0.36
! 1 Warning Sign
View Full Analysis

What is Anebulo Pharmaceuticals YoY EPS Growth?

Anebulo Pharmaceuticals ANEB -8.05% 35 YoY EPS Growth is 44.44% as of Dec. 2025. GuruFocus rates ANEB with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Anebulo Pharmaceuticals's YoY EPS Growth for the quarter that ended in Dec. 2025 was 44.44%.

Anebulo Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Dec. 2025 was $-0.05.

Anebulo Pharmaceuticals YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Anebulo Pharmaceuticals's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anebulo Pharmaceuticals YoY EPS Growth Chart

Anebulo Pharmaceuticals Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY EPS Growth
Get a 7-Day Free Trial 0.00 89.75 -62.07 31.91 21.88

Anebulo Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.18 33.33 0.00 37.50 44.44
ANEB
35GF Score
Anebulo Pharmaceuticals Inc ANEB
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anebulo Pharmaceuticals YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Anebulo Pharmaceuticals's YoY EPS Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EPS Growth (A: Jun. 2025 )
=(Earnings per Share (Diluted) (A: Jun. 2025 )-Earnings per Share (Diluted) (A: Jun. 2024 ))/ | Earnings per Share (Diluted) (A: Jun. 2024 ) |
=(-0.25--0.32)/ | -0.32 |
=21.88 %

Anebulo Pharmaceuticals's YoY EPS Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EPS Growth (Q: Dec. 2025 )
=(Earnings per Share (Diluted) (Q: Dec. 2025 )-Earnings per Share (Diluted) (Q: Dec. 2024 )) / | Earnings per Share (Diluted) (Q: Dec. 2024 )) |
=(-0.05--0.09)/ | -0.09 |
=44.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 44.44% mean?
Anebulo Pharmaceuticals (ANEB) has a YoY EPS Growth of 44.44% as of Dec. 2025. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Anebulo Pharmaceuticals and its competitors.
Is Anebulo Pharmaceuticals' YoY EPS Growth too high?
Anebulo Pharmaceuticals' current YoY EPS Growth is 44.44%. Overall, Anebulo Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Anebulo Pharmaceuticals' YoY EPS Growth compare to PHIO and MBRX?
Anebulo Pharmaceuticals' YoY EPS Growth of 44.44% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Anebulo Pharmaceuticals and its competitors. Anebulo Pharmaceuticals's current YoY EPS Growth is 44.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anebulo Pharmaceuticals stock overvalued right now?
Anebulo Pharmaceuticals (ANEB) has a current YoY EPS Growth of 44.44%. The current YoY EPS Growth is 44.44%. Anebulo Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Anebulo Pharmaceuticals (ANEB), the current YoY EPS Growth is 44.44% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anebulo Pharmaceuticals Business Description

Address 1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
35GF Score

Get the complete analysis for ANEB

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.36
Price